Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.

摘要: In view of the clinical potential a number natural products, Combretastatin A-1 phosphate was developed as water-soluble derivative combretastatin A-1. This study examined anti-tumour activity this compound against an experimental colon tumour (MAC29) in mice. A comparison made with clinically active A-4 phosphate. The new well-tolerated up to dose 250 mg/kg and more effective at producing growth delays than analogue. Significant were seen 50 whereas produced no measurable delay until 150 administered. Histological examination treated tumours indicated that caused very severe haemorrhagic necrosis tissue analysis sections almost 94 percent dead within 24 hours treatment. mechanism action appears be similar vascular shutdown occurs 4 summary phosphate, analogue A-1, is potent well-vascularised murine its predecessor, These data suggest may have for development.